Email This Article

Headlines & Perspectives
Introgen Critically Hurt by FDA Advexin Snub
By Adam Feuerstein
09/02/08 - 11:15 AM EDT
The regulator refused to accept an approval application for the gene therapy cancer drug, dealing a devastating blow to the company.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,452.68 1,109.24 2,185.03 33.23
Oil *
77.73
DOWN
18.90
UP
0.38
UP
9.22
UP
0.48
10 Yr
3.32%
SPDR Gold
119.18
-0.18%
+0.03%
+0.42%
+1.47%
Data delayed 20 minutes

Brokerage Partners